A number of potentially useful approaches for the therapy of acquired immunodeficiency syndrome (AIDS) and its related diseases have emerged. The use of family of 2',3'-dideoxynucleotides, such as 3'-azido-2',3'-dideoxythymidine (AZT or zidovudine), 2',3'dideoxycytidine (ddC or zalcitabine), and 2',3'-dideoxyinosine (ddI or didanosine), which target the reverse transcriptase of human immunodeficiency virus type I (HIV-1), the causative agent of AIDS, is one such approach. HIV also codes a virus-specific aspartic protease which is essential for its replication. The HIV protease mediates crucial proteolytic processing of viral protein precursors at a late stage in the replication of the virus. Thus, HIV protease also represents a virus-specific target for the therapy of HIV infections.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01CM006739-01
Application #
3838110
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Division of Cancer Treatment
Department
Type
DUNS #
City
State
Country
United States
Zip Code